Gold bars to be exempt from tariffs, White House clarifies
On Monday, Stifel analysts revised the price target for Neumora Therapeutics (NASDAQ:NMRA) shares, reducing it significantly from $26.00 to $6.00, while continuing to endorse the stock with a Buy rating. Currently trading at $1.53, the stock has fallen 91% over the past year and sits near its 52-week low of $1.51. The adjustment follows Neumora’s announcement of modifications to its KOSTAL-2/3 clinical studies, which are aimed at enhancing trial procedures and boosting the chances of success. According to InvestingPro analysis, the stock appears undervalued at current levels.
Stifel’s commentary highlighted the heightened risk profile for Neumora following the outcomes of the KOSTAL-1 trial, which is now factored into the new price target. Despite the uncertainties surrounding the failure of the KOSTAL-1 study, whether due to study issues or the drug’s efficacy, analysts at Stifel find the risk/reward balance for Neumora to be compelling, particularly noting that the stock is trading below cash value. With a market capitalization of $252 million and a price-to-book ratio of 0.79, InvestingPro data shows the stock’s RSI indicates oversold conditions.
The firm’s analysts pointed out that failures in major depressive disorder (MDD) clinical trials are not uncommon, citing recent examples such as Spravato and Vraylar. They believe that with the stock’s current valuation and the planned study adjustments, the investment opportunity in Neumora remains attractive.
Neumora’s implementation of the changes to its clinical trials is expected to delay data outcomes until the first and second quarters of 2026. Stifel suggests that this timeline could provide a buffer in case Neumora decides to increase its funding. The company’s cash runway is acknowledged as tight, but Neumora has provided guidance indicating sufficient funds until mid-2026. InvestingPro analysis reveals a strong current ratio of 10.98, indicating solid short-term liquidity position. Discover 12 additional ProTips and comprehensive financial metrics for NMRA with an InvestingPro subscription, including detailed analysis of the company’s financial health and growth potential.
In other recent news, Neumora Therapeutics reported a significant earnings surprise for Q4 2024, posting an earnings per share (EPS) of -$0.37, which was better than the expected -$0.62. This improvement was attributed to strategic cost reductions, with operating expenses for the quarter dropping to $58.8 million from $108.7 million the previous year. The company maintains a solid cash position of $307.6 million, projected to support operations until mid-2026. Neumora is advancing its product pipeline with key programs, including the Phase 3 COASTAL program for Major Depressive Disorder, with results expected in 2026. The company also reported discontinuing a Phase 2 trial for bipolar depression to focus resources on other clinical programs. Neumora remains committed to developing treatments for brain diseases, with plans to report data from the NMRA-511 study in Alzheimer’s disease agitation by the end of 2025. The company’s strategic focus on high-potential programs and disciplined financial management reflects its strong position in the competitive landscape of brain disease treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.